Global Blood Therapeutics
171 Oyster Point Blvd., Suite 300
South San Francisco
Tel: (650) 741-7700
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.
115 articles with Global Blood Therapeutics
GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program
The data were presented in oral and poster sessions during the 59th American Society of Hematology (ASH) Annual Meeting & Exposition at the Georgia World Congress Center in Atlanta.
The HOPE-KIDS 1 Study is an ongoing open-label, single- and multiple-dose study evaluating the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor in a pediatric population with SCD.
The first employee received an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $39.25, the closing trading price on the grant date of November 28, 2017.
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Mo...
11/13/2017Based on DSMB review, patients age 12 to 17 can now be enrolled in the phase 3 hope study.
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
Cash, cash equivalents and marketable securities totaled $259.4 million at September 30, 2017, compared with $197.3 million at December 31, 2016.
Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient With Severe and Symptomatic Anemia
The patient received the investigational agent through single-patient compassionate access.
Global Blood Therapeutics Announces Approval of First-in-Class 'Voxelotor' as Nonproprietary Name for GBT440
Voxelotor is an oral, once-daily therapy that is designed to modulate hemoglobin affinity for oxygen and is in clinical development for the treatment of sickle cell disease.
The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).
Global Blood Therapeutics Announces Presentation Of New Data Showing Positive Effect Of GBT440 On Sickle Cell Disease Patient With Variant Genotype
Global Blood Therapeutics To Convene Sickle Cell Disease Influencers At Annual Sickle Cell Disease (SCD) Therapeutics Conference
Global Blood Therapeutics Receives Rare Pediatric Disease Designation From FDA For GBT440 For Treatment Of Sickle Cell Disease (SCD)
Global Blood Therapeutics Reports Recent Business Progress And Provides Second Quarter 2017 Financial Results
Global Blood Therapeutics Expands Ongoing Phase IIa HOPE-KIDS 1 Study Into Younger Pediatric Population
Global Blood Therapeutics Receives EMA PRIME Designation For GBT440 For The Treatment Of Sickle Cell Disease (SCD)
Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development Of GBT440 In Adolescents With Sickle Cell Disease
Global Blood Therapeutics Reports Recent Business Progress And Provides First Quarter 2017 Financial Results
Global Blood Therapeutics Reports Recent Business Progress And Fourth Quarter And Year-End 2016 Financial Results
Global Blood Therapeutics Announces Closing Of Public Offering Of Common Stock Including Full Exercise Of Option To Purchase Additional Shares